Marpai, Inc.

OTCPK:MRAI Stock Report

Market Cap: US$7.4m

Marpai Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Marpai.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Insurance earnings growth1.8%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Analysis Article • Apr 07

Revenues Not Telling The Story For Marpai, Inc. (NASDAQ:MRAI) After Shares Rise 30%

Marpai, Inc. ( NASDAQ:MRAI ) shares have continued their recent momentum with a 30% gain in the last month alone. Not...
Analysis Article • Feb 16

Investors Still Aren't Entirely Convinced By Marpai, Inc.'s (NASDAQ:MRAI) Revenues Despite 34% Price Jump

Marpai, Inc. ( NASDAQ:MRAI ) shareholders have had their patience rewarded with a 34% share price jump in the last...
Analysis Article • Dec 19

Market Might Still Lack Some Conviction On Marpai, Inc. (NASDAQ:MRAI) Even After 106% Share Price Boost

Marpai, Inc. ( NASDAQ:MRAI ) shares have continued their recent momentum with a 106% gain in the last month alone. Not...
Analysis Article • Jun 29

Not Many Are Piling Into Marpai, Inc. (NASDAQ:MRAI) Stock Yet As It Plummets 28%

To the annoyance of some shareholders, Marpai, Inc. ( NASDAQ:MRAI ) shares are down a considerable 28% in the last...
Seeking Alpha • Aug 19

Marpai rallies after directors buy shares

Marpai (NASDAQ:MRAI) stock is up 9% in premarket trading on Friday after the director increased their holdings in the tech-driven healthcare services provider, as per the latest SEC filings. Director Yaron Eitan bought 1,75,000 shares at the price of $0.79 each, taking his direct beneficial ownership to 9,65,816 shares. Vincent Kane has also bought 6,500 shares at the price range of $0.78 to $0.83 each. The transaction takes Kane's direct beneficial ownership to 71,169 shares. Quick look through company's ownership structure:
Seeking Alpha • Aug 04

Marpai to acquire Maestro Health for $22.1M

Marpai (NASDAQ:MRAI) said Thursday it will acquire Maestro Health, a third-party administrator based in Chicago, Illinois, for $22.1M. The purchase price will be payable in cash on Apr. 1, 2024. Subject to MRAI meeting its obligations under the deal, this payment may be financed over 4 years by the seller. This comprises minimum annual cash payments of $5M, $6M, $8M and $9M payable on Dec. 31, 2024, 2025, 2026 and 2027, respectively. MRAI agreed that a minimum of 35% of net proceeds of any equity offering will be used to pre-pay its minimum payment obligations. The parties agreed that Maestro's free cash position at closing will be $15.79M and it will have certain minimum working capital amounts at closing. Cash on the combined firm's balance sheet (of over $20M) and synergies from the deal are expected to drive the joint company's plan of integration, which is expected to include a target of reaching positive EBITDA within 18 months. The combined company will serve over 40K employee lives, with expected combined proforma annual revenues of ~$40M in 2022. The acquisition is expected to more than double MRAI's revenues and number of customers. The deal is expected to close in 60 days.

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Marpai has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

OTCPK:MRAI - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/202617-17-8-8N/A
12/31/202518-17-7-7N/A
9/30/202521-12-7-7N/A
6/30/202524-12-12-12N/A
3/31/202526-21-12-12N/A
12/31/202428-22-15-15N/A
9/30/202430-26-11-11N/A
6/30/202432-30-14-14N/A
3/31/202435-24-13-13N/A
12/31/202337-29-16-16N/A
9/30/202336-32-35-35N/A
6/30/202332-31-34-34N/A
3/31/202328-30-39-38N/A
12/31/202224-26-36-35N/A
9/30/202223-24-22-21N/A
6/30/202222-23-17-16N/A
3/31/202220-20-15-13N/A
12/31/202114-16-13-11N/A
9/30/20218-11-8-6N/A
6/30/20214-7-7-6N/A
3/31/2021N/A-4-3-2N/A
12/31/2020N/A-4-3-2N/A
9/30/2020N/A-4-2-2N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if MRAI's forecast earnings growth is above the savings rate (3.5%).

Earnings vs Market: Insufficient data to determine if MRAI's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if MRAI's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if MRAI's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if MRAI's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if MRAI's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/18 11:40
End of Day Share Price 2026/05/15 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Marpai, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Allen KleeMaxim Group
null nullMaxim Group
Ashok KumarThinkEquity LLC